AI Insight
GLP-1 receptor agonists have transformed treatment for type 2 diabetes and obesity by improving blood sugar control, weight management, and cardiovascular and kidney health outcomes. Researchers are now exploring whether targeting multiple hormone receptors simultaneously could provide even better results. Early evidence shows that tirzepatide, a dual agonist targeting both GLP-1 and GIP receptors, produces greater reductions in HbA1c and body weight compared to the single GLP-1 agonist semaglutide in people with type 2 diabetes.
Why it matters
This approach could lead to more effective treatments for metabolic diseases by combining multiple biological targets in a single medication. If successful, multi-receptor therapies may offer patients better metabolic control with potentially fewer medications and improved clinical outcomes.
GLP-1 receptor agonists have revolutionised the care of people with type 2 diabetes and obesity, because they are highly effective for glycaemic control and chronic weight management while delivering improved cardiovascular and kidney outcomes.1,2 Building on the success of single GLP-1 receptor agonism, it is hoped that modulation of additional nutrient-stimulated hormone receptors will deliver better value through greater efficacy, broader metabolic benefits, or improved tolerability. Indeed, tirzepatide (at doses of 5 mg, 10 mg, or 15 mg), a unimolecular dual agonist of both GLP-1 and gastric inhibitory polypeptide (GIP) receptors, induces greater improvements in glycated haemoglobin (HbA1c) and weight than the GLP-1 receptor agonist semaglutide (1 mg) in people with type 2 diabetes.
Source: [Comment] Multireceptor modulation in metabolic disease: are more targets better?